Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO
Attovia Therapeutics, a Goldman Sachs-backed biotech company specializing in treatments for immune-mediated diseases, is planning to go public with an IPO targeting $212.5 million in funding. The company aims to address medical conditions with significant unmet treatment needs in the immunology space.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending